Loading…
Runs comprehensive molecular tumor profiling (DNA/RNA sequencing) to help oncologists match cancer patients to targeted therapies.
Runs comprehensive molecular tumor profiling (DNA/RNA sequencing) to help oncologists match cancer patients to targeted therapies.
Paid per test: Medicare and private insurers reimburse the lab for each tumor-sequencing report, while drug makers pay for access to its anonymised molecular and outcomes data and for companion-diagnostic development. Volumes depend on oncologists ordering the test and insurers agreeing to pay.
Moat: narrow (data, process know-how, scale). A large proprietary tumor molecular/clinical-outcomes database supports AI-driven biomarker discovery that is hard to replicate quickly.
Headquarters: Irving, Texas, US · Founded: 2008 · Employees: 1,846
Size Caris Life Sciences (CAI) is a United States Health Care company (Biotechnology) with a market value of $7.13B, the 951st largest of 3,117 United States companies the cockpit tracks. Shares closed at $25.23 on 6 Nov 2026.
Performance Over six months the shares gained 56.2%, against -1.4% for the median peer and -1.1% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 85.4% over the last twelve months (peer median +20.5%); the operating margin is 15.5% (peer median -2.3%).
Valuation It trades at 86.1× forward earnings against a peer median of 58.5× (2nd most expensive of 9).
Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +85%, so the hurdle is -67 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 40.0 points above its cost of capital (8.2% WACC).
Short interest Short interest is 4.8% of the free float (15 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | $990M | $812M | $412M | $306M |
| Revenue growth | — | +97% | +35% | — |
| Gross profit | $689M | $539M | $179M | $89.3M |
| EBITDA | $174M | $67.7M | -$208M | -$271M |
| Net income | $105M | -$68.1M | -$282M | -$341M |
| Free cash flow | $116M | $59.2M | -$254M | -$298M |
| Capital expenditure | $44.6M | $16.3M | $8.44M | $22.3M |
| Total debt | $452M | $428M | $424M | $217M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Caris Life Sciences CAI | $7.13B | +56% | +85% | 15% | 86.1× | 18.7% |
| Roche RO.SW | $385B | +22% | -1% | 31% | 19.6× | 0.9% |
| Guardant Health GH | $20.2B | +58% | +43% | -40% | n/a | n/a |
| Tempus AI TEM | $13.9B | +53% | +37% | -18% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CAI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.2% | -2.0% | 7th lowest of 21 |
| 6-month return | +56.2% | -1.4% | 5th highest of 21 |
| Distance from 52-week high | -30.9% | -30.5% | 11th highest of 21 |
| Revenue growth (TTM) | +85.4% | +20.5% | 3rd highest of 15 |
| Operating margin | 15.5% | -2.3% | 6th highest of 15 |
| Forward P/E | 86.1× | 58.5× | 2nd most expensive of 9 |
| Growth the price implies (Req g, 7 yrs) | 18.7% | 29.8% | 3rd least demanding of 8 |
| Growth delivered (Del g) | +85.4% | +19.8% | highest of 8 |
| Hurdle (Req g minus delivered) | -66.7 pp | +10.5 pp | least demanding of 8 |
| ROIC minus cost of capital | +40.0 pp | -6.8 pp | highest of 13 |
| EV / EBITDA | 39.0× | 39.8× | 3rd cheapest of 5 |
| Net debt / EBITDA | -2.0× | -2.1× | 3rd least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Caris Life Sciences CAI | United States | $7.13B | +56% | +85% | 15% | 86.1× | 18.7% | +85.4% |
| Axsome Therapeutics AXSM | United States | $6.96B | -39% | +54% | -19% | 75.5× | n/a | n/a |
| CG Oncology CGON | United States | $6.74B | +9% | +1,030% | -4,056% | n/a | n/a | n/a |
| 10x Genomics TXG | United States | $7.72B | +174% | -4% | -14% | n/a | 41.8% | +16.6% |
| Twist Bioscience TWST | United States | $7.95B | +112% | +19% | -32% | n/a | n/a | n/a |
| Immunovant IMVT | United States | $6.31B | +5% | n/a | n/a | n/a | n/a | n/a |
| Kodiak Sciences KOD | United States | $6.24B | +142% | n/a | n/a | n/a | n/a | n/a |
| Arrowhead Pharmaceuticals ARWR | United States | $8.22B | -20% | +17% | -34% | n/a | n/a | n/a |
| Genscript Biotech 1548.HK | Hong Kong | $8.81B | +96% | +53% | 12% | 297.9× | 36.5% | +19.8% |
| Scholar Rock SRRK | United States | $5.72B | -3% | n/a | n/a | n/a | n/a | n/a |
| Krystal Biotech KRYS | United States | $8.92B | -2% | +26% | 48% | 34.7× | 11.9% | +26.0% |
| Hangzhou Tigermed Consulting 3347.HK | Hong Kong | $5.65B | -1% | +22% | 10% | 71.8× | 28.3% | +15.6% |
| Cogent Biosciences COGT | United States | $5.49B | -9% | n/a | n/a | n/a | n/a | n/a |
| Anthem Biosciences ANTHEM.NS | India | $5.46B | +17% | -1% | 35% | 69.9× | 36.7% | +26.2% |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.35B | -2% | -28% | -210% | n/a | -6.4% | -10.0% |
| Vaxcyte PCVX | United States | $10.1B | +21% | n/a | n/a | n/a | n/a | n/a |
| ALTEOGEN 196170.KS | South Korea | $10.3B | -46% | +61% | 53% | 47.0× | 29.8% | +38.5% |
| 3SBio 1530.HK | Hong Kong | $4.92B | -34% | +102% | 61% | 13.7× | n/a | n/a |
| Edgewise Therapeutics EWTX | United States | $4.89B | +28% | n/a | n/a | n/a | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.89B | -11% | -22% | 17% | 13.7× | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $4.86B | -9% | -34% | -2,059% | n/a | n/a | n/a |